Research Center del Cancer Institute Biologia Molecular lular del Cancer
Matarraz S.,Research Center del Cancer Institute Biologia Molecular lular del Cancer |
Lopez A.,Research Center del Cancer Institute Biologia Molecular lular del Cancer |
Barrena S.,Research Center del Cancer Institute Biologia Molecular lular del Cancer |
Fernandez C.,Research Center del Cancer Institute Biologia Molecular lular del Cancer |
And 12 more authors.
Cytometry Part B - Clinical Cytometry | Year: 2010
A heterogeneous spectrum of immunophenotypic abnormalities have been reported in myelodysplastic syndromes (MDS). However, most studies are restricted to the analysis of CD34+ cells and/or other major subsets of CD34- cells, frequently not exploring the diagnostic and prognostic impact of immunophenotyping. Methods: We propose for the first time an immunophenotypic score (IS) based on the altered distribution and immunophenotypic features of maturing/mature compartments of bone marrow (BM) hematopoietic cells in 56 patients with MDS that could contribute to a refined diagnosis and prognostic evaluation of the disease. Results: Although MDS-associated phenotypes were detected in reactive BM, the overall immunophenotypic profile of BM cells allowed an efficient discrimination between MDS and both normal and reactive BM, once the number and degree of severity of the abnormalities detected per patient were simultaneously considered in the proposed IS. Interestingly, increasingly higher IS were found among patients with MDS showing adverse prognostic factors and in low- versus high-grade cases. The most informative prognostic factors included the number of CD34+ cells, presence of aberrant CD34-/CD117+ precursors, decreased mature neutrophils and CD34- erythroid precursors, and increased numbers of CD361/lo erythroid precursors; in addition, the IS was an independent prognostic factor for overall survival. Conclusions: Assessment of immunophenotypic abnormalities of maturing/mature BM cells allows an efficient discrimination between MDS and both normal and reactive BM, once the number and degree of severity of the abnormalities detected are simultaneously scored. Interestingly, progressively higher IS were found among patients with MDS with adverse prognostic features and shorter overall survival. © 2010 Clinical Cytometry Society.
Vano-Galvan S.,Hospital Universitario Ramon jal |
Alvarez-Twose I.,Hospital Virgen del Valle |
Alvarez-Twose I.,Research Center del Cancer Institute Biologia Molecular lular del Cancer |
De Las Heras E.,Hospital Universitario Ramon jal |
And 13 more authors.
Archives of Dermatology | Year: 2011
Objectives: To evaluate dermoscopic features in a group of 127 patients with mastocytosis in the skin and to investigate the relationship between different dermoscopic patterns and other clinical and biological characteristics of the disease. Design: Clinical and laboratory data were compared among patients with mastocytosis grouped according to the different dermoscopic patterns. Setting: Patients were selected from the Instituto de Estudios de Mastocitosis de Castilla La Mancha and the Department of Dermatology of Hospital Universitario Ramón y Cajal from April 1 through September 30, 2009. Patients: Overall, 127 consecutive patients (70 females [55.1%] and 57 males [44.9%]; median age, 17 years; range, 0-81 years) with mastocytosis in the skin were included in the study. Main Outcome Measures: Evaluation of dermoscopic patterns and investigation of potential predictive factors for more symptomatic forms of the disease according to the need for daily antimediator therapy. Results: Four distinct dermoscopic patterns were observed: yellow-orange blot, pigment network, reticular vascular pattern, and (most frequently) light-brown blot. A reticular vascular pattern was identified in all telangiectasia macular eruptiva and some maculopapular mastocytosis. In turn, all patients with mastocytoma displayed the yellow-orange blot pattern. The reticular vascular dermoscopic pattern was associated with the need for daily antimediator therapy; this pattern, together with serum tryptase levels and plaque-type mastocytosis, represented the best combination of independent factors to predict the need for maintained antimediator therapy. Conclusions: Dermoscopy is a feasible method for the subclassification of mastocytosis. Of note, a reticular vascular pattern is more frequently associated with the need for antimediator therapy. ©2011 American Medical Association. All rights reserved.